Key Record Dates
| ClinicalTrials.gov Identifier: | NCT04300556 |
|---|---|
| Brief Title: | A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types |
| First Submitted : | March 6, 2020 |
| First Submitted that Met QC Criteria : | March 6, 2020 |
| First Posted : | March 9, 2020 |
| Last Update Submitted that Met QC Criteria : | January 30, 2023 |
| Last Update Posted : | January 31, 2023 |